ADMA Biologics (ADMA) PT Raised to $14 at Oppenheimer; 'Refinancing Provides Some Breathing Room'
Tweet Send to a Friend
Oppenheimer analyst Leland Gershell raised the price target on ADMA Biologics (NASDAQ: ADMA) to $14.00 (from $13.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
